IVVD

Invivyd, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1832038Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$53.0M

Net Income FY2025

$(52.0M)

EPS (Basic, as reported)

$-0.30

Net Margin FY2025

-98.2%

ROE FY2025

-21.7%

Total Equity

$242.0M

Shares Out

295M

Business description

Invivyd, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 53

Fiscal yearFY2020FY2021⚑FY2022FY2023FY2024⚑FY2025

Revenue———02553

Research & development—(183)(179)(159)(137)(38)

Selling, general & administrative—(37)(47)(49)(63)(67)

Total operating expenses—(227)(248)(213)(202)(109)

Operating income—(227)(248)(213)(177)(56)

Other income (expense), net—071473

Income tax expense—00000

Net income—(39)(241)(199)(170)(52)

EPS — basic—($5.32)($2.23)($1.81)($1.43)($0.30)

EPS — diluted—($5.32)($2.23)($1.81)($1.43)($0.30)

Shares outstanding — basic (M)—43108110119172

Shares outstanding — diluted (M)—43108110119172

⚑ Weighted-average shares changed ×2.51 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.45 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.